Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1767-1776

  Yao, Ninghua ^a   Yao, Dengfu ^a   Wang, Li ^a   Dong, Zhizhen ^a   Wu, Wei ^a   Qiu, Liwei ^a   Yan, Xiaodi ^a   Yu, Dandan ^a   Chen, Jie ^a   Sai, Wenli ^a   Zhang, Haijian ^a   Yang, Junlin ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Extrahepatic metastasis; Hepatocellular carcinoma; Insulin like growth factor II; Targeted therapy

Indexed keywords

MESSENGER RNA; MICRORNA; SOMATOMEDIN B; VASCULOTROPIN;

ANGIOGENESIS; ANOIKIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SUPERNATANT;

EID: 84868087863     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0436-x     Document Type: Article

References (31)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118- 27.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134(6):1752-63.
4. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72 Suppl 1:2-15.
5. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27(1):55-76.
6. Toffanin S, Friedman SL, Llovet JM. Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. Cancer Cell. 2010;17(2):115-7.
7. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008;47(3):908-18.
8. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28(1):20-47.
9. Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Color Dis. 2005;20(3):203-20.
10. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6(3):241-7.
11. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999;19(10):7203-15.
12. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;25(27):3787-800.
13. Wilkin F, Gagne N, Paquette J, Oligny LL, Deal C. Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene over-expression. J Clin Endocrinol Metab. 2000;85(5):2048-56.
14. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 2010;52(4):550-9.
15. Qian J, Yao D, Dong Z, Wu W, Qiu L, Yao N, et al. Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol. 2010;134(5):799-806.
16. Yao NH, Yao DF, Qian J, Dong ZZ, Qiu LW, Yu DD. Construction of expression plasmids carrying miRNA targeting IGF-II and detection of their inhibitory effect on IGF-II expression in human HepG2 cells. Shijie Huaren Xiaohua Zazhi. 2011;19(10):1015-21. in Chinese.
17. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 1988;48(23):6844-9.
18. Qiu LW, Yao DF, Zong L, Lu YY, Huang H, Wu W, et al. Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development. Hepatobiliary Pancreat Dis Int. 2008;7(4):406-11.
19. Yao X, Hu JF, Daniels M, Yien H, Lu H, Sharan H, et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res. 2003;9(7):2719-26.
20. Kimura T, Kuwata T, Ashimine S, Yamazaki M, Yamauchi C, Nagai K, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res. 2010;16(1):121-9.
21. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology. 2008;48(1):146-56.
22. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature. 2003;422(6934):835-47.
23. Grunweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 2003;31(12):3185-93.
24. Ding SW, Voinnet O. Antiviral immunity directed by small RNAs. Cell. 2007;130(3):413-26.
25. Chen Y, Xie D, Yin Li W, Man Cheung C, Yao H, Chan CY, et al. RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett. 2010;297(1):109-16. PMID: 20684863.
26. Lin RX, Wang ZY, Zhang N, Tuo CW, Liang QD, Sun YN, et al. Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model. Hepatol Res. 2007;37(5):366-75.
27. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA. 2010;107(24):10791-8.
28. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 1998;58(2):348-51.
29. Kim HJ, Kim TY. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C. Br J Dermatol. 2005;152(3):418-25.
30. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751, 871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009;69(19):7662-71.
31. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177-85.